AAPK-25 NEW
| Price | $52 | $127 | $191 |
| Package | 1mg | 5mg | 10mg |
| Supply Ability: | 10g |
| Update Time: | 2026-04-21 |
Product Details
| Product Name: AAPK-25 | CAS No.: 2247919-28-2 |
| Purity: 97.79% | Supply Ability: 10g |
| Release date: 2026/04/21 |
Product Introduction
Bioactivity
| Name | AAPK-25 |
| Description | AAPK-25 is a potent and selective Aurora/PLK dual inhibitor with anti-tumor activity, causing mitotic delay and arresting cells in prometaphase, followed by increased apoptosis. It targets Aurora-A/-B/-C with Kd values ranging from 23-289 nM. |
| In vitro | AAPK-25 inhibits the growth of HCT-116, Calu6, A549, and MCF-7 cells (IC50s: 0.4, 5.3, 11.6, and 2.3 μM). It induces apoptosis in a dose-dependent manner in the HCT-116 cell line, significantly increases histone H3Ser10 phosphorylation, indicating a marked mitotic block, and notably inhibits the mitotic spindle checkpoint. |
| In vivo | AAPK-25 enhances the survival rate in the BALB/c nude mice tumor xenograft model. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 50 mg/mL (113.04 mM), Sonication is recommended. |
| Keywords | Polo-like Kinase (PLK) | PLK3 | PLK2 | PLK1 | Inhibitor | inhibit | AuroraKinase | Aurora Kinase | Aurora C | Aurora B | Aurora A | Apoptosis | AAPK-25 | AAPK25 | AAPK 25 |
| Inhibitors Related | Stavudine | Aceglutamide | Urea | Tamoxifen | Cysteamine hydrochloride | Metronidazole | Citric Acid Triammonium | Formamide | Dimethyl phthalate | Alginic acid | Sodium Molybdate | Sildenafil citrate |
| Related Compound Libraries | Apoptosis Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Epigenetics Compound Library | Kinase Inhibitor Library | Multi-Target Compound Library | Post-Translational Modification Compound Library | Inhibitor Library | Bioactive Compounds Library Max | Cell Cycle Compound Library | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $1.00 |
VIP3Y
|
Jinan Million Pharmaceutical Co., Ltd
|
2026-07-07 | |
|
VIP2Y
|
Changsha YuTeng New Materials Co., Ltd.
|
2026-07-03 | ||
| $52.00 |
VIP4Y
|
TargetMol Chemicals Inc.
|
2026-04-21 | |
| $87.00 |
VIP2Y
|
TargetMol Chemicals Inc.
|
2025-04-28 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY